X4 Pharmaceuticals News and Activities

X4 Pharmaceuticals is a company listed under the stock ticker XFOR (US).

View the org chart displaying its 12 main executives

Most searched biographies at X4 Pharmaceuticals

• Gary Bridger, Director
• Murray Stewart, Director
• Adam Craig, Executive Chairman of the Board

Create your alert
to follow the executive moves at X4 Pharmaceuticals.

X4 Pharmaceuticals has 1,913 competitors including Sanofi (France), Moderna (United States (USA)) and Eli Lilly (United States (USA)).

Popular M&A news in Pharmaceuticals

• Eli Lilly has acquired Centessa Pharmaceuticals (posted on June 24 2026).
• Polpharma has acquired Biofarm (posted on June 24 2026).
• AbbVie has announced the acquisition of Apogee Therapeutics  (posted on June 23 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Tracey Franklin - Chief People and Digital Technology Officer at Moderna
• Richard Saynor - Chief Executive Officer at Sandoz

Learn more about the Pharmaceuticals industry

Press releases by X4 Pharmaceuticals

• X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference | X4 Pharmaceuticals, Inc.
• X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update | X4 Pharmaceuticals, Inc.
• X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union | X4 Pharmaceuticals, Inc.
• X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | X4 Pharmaceuticals, Inc.
• X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | X4 Pharmaceuticals, Inc.
• X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference | X4 Pharmaceuticals, Inc.
• X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | X4 Pharmaceuticals, Inc.
• X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome | X4 Pharmaceuticals, Inc.
• X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026 | X4 Pharmaceuticals, Inc.
• X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | X4 Pharmaceuticals, Inc.
• View more press releases Close

Social media about X4 Pharmaceuticals

• X4 Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• X4 Pharmaceuticals on LinkedIn, X (Twitter) & YouTube